Penn State Cancer Institute offers lifesaving lymphoma treatment
For people with an aggressive form of non-Hodgkin lymphoma, treatments can be limited. Enter a new treatment called Yescarta. Yescarta, or axicabtagene ciloleucel, can be nothing short of “miraculous” for these patients, according to Dr. Shin Mineishi, a medical oncologist at Penn State Cancer Institute. Based on the campus of Penn State Health Milton S. Hershey Medical Center, the Cancer Institute is the only hospital in central Pennsylvania that offers this last-resort treatment for certain cancer patients.
The U.S. Food and Drug Administration (FDA) approved Yescarta in October 2017 for adult patients with a type of non-Hodgkin lymphoma called large B-cell lymphoma if their cancer fails to respond to chemotherapy or returns after two or more treatments. Yescarta is for adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Diffuse large B-cell lymphoma is the most common type of adult non-Hodgkin lymphoma. Approximately 30,000 people in the U.S. are diagnosed with it every year, according to the FDA. People with this form of cancer have rapidly growing tumors in their lymph nodes, spleen, liver, bone marrow or other organs.
Mineishi says that most patients can be treated with chemotherapy. Unfortunately, some of those who don’t respond to the standard treatments may progress quickly and die.
Yescarta, which is part of a growing field called immunotherapy, could be a game-changer for these patients who have exhausted all other options. In a clinical trial published in the New England Journal of Medicine in December 2017, 82 percent of 101 patients who received Yescarta responded to the treatment, with 54 percent of the recipients in complete remission. A year and a half after the treatments, 52 percent of the patients were still alive.
What is chimeric antigen receptor (CAR) T-cell therapy?
In the U.S., Yescarta is one of only two approved chimeric antigen receptor (CAR) T-cell therapy, which boost the body’s immune system against cancer. In these treatments, a patient’s own T cells, a type of white blood cell, are modified to better target their tumor cells.
“CAR T-cell therapy is one of the most important therapies to hit oncology in the past 20 years,” says Dr. Raymond Hohl, director of Penn State Cancer Institute. “It can put people who don’t respond to standard treatments into remission and it can potentially cure them of their cancers. So this is a very, very exciting approach.”
In this technique, a patient’s own T cells are removed from their blood and modified to have special receptors on their surface called chimeric antigen receptors (CARs). These receptors are important because they recognize and attach to proteins on tumor cells. The modified T cells—called CAR T cells—are expanded and then infused back into the patient. When the CAR T cells recognize the tumor cells, they proliferate and attack.
Mineishi says that in the days leading up to the infusion, patients will receive weak doses of chemotherapy to slightly suppress their immune system. Once the infusion is ready to be administered, patients will be admitted to the bone marrow transplant in-patient service. There, they’ll be monitored daily for at least two weeks following the treatment. After being discharged from the hospital, they’ll be asked to check in a few times a week during the first two months. After that, they should be able to resume their normal appointments.
What’s more, patients who are in remission after CAR T may be able to receive bone marrow transplants, Hohl says, which could increase the chance of their cancer being cured.
Read the complete article on Penn State Medicine.
If you're having trouble accessing this content, or would like it in another format, please email Penn State Health Marketing & Communications.